Prosensa Holding (RNA), up 35% after reporting what the company called "encouraging" results from a Phase II trial of drisapersen for the treatment of Duchenne Muscular Dystrophy..
Currently bid 8.47, not a hell of a lot of volume, though
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.